Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Ripretinib
DCC-2618 · 2 trials · 2 indications
PFS is defined as the time interval from randomization to the first occurrence of progressive disease based on assessment of the independent radiology review (IRR) or death due to any causes.
| Arm | Type | Description |
|---|---|---|
| Ripretinib | EXPERIMENTAL | 50mg/tablet,150 mg QD continuous administration, 6 weeks (42 days) for a cycle. |
| Sunitinib | ACTIVE_COMPARATOR | 12.5mg/capsule, 50 mg QD, in 6 weeks (42 days) with 4 weeks continuous dosing followed by 2 weeks break. |
| DCC-2618 | EXPERIMENTAL | DCC-2618 drug is 50mg per tablet, 150mg once a day, with 28 days as a treatment cycle. |
| Name | Type | Description |
|---|---|---|
| Ripretinib | DRUG | Oral kinase inhibitor |
| Sunitinib | DRUG | second-line therapy in GIST patients who have progressed after imatinib treatment or are intolerant to imatinib |
| DCC-2618 | DRUG | Oral kinase inhibitor |
Inclusion Criteria: * Male or female patients ≥18 years of age. * Histological diagnosis of advanced GIST and capability of providing tumor tissue sample (the interval between tumor tissue collection and signing of informed consent form should be less than 3 years). Otherwise, biopsy is required. *...
DCC-2618 is a small molecule being studied for the treatment of advanced gastrointestinal stromal tumors (GIST). It is an investigational drug currently in clinical development and has not been approved by regulatory authorities.
DCC-2618 is being developed by Zai Lab Limited, a biopharmaceutical company traded on the NASDAQ under the ticker symbol ZLAB. The company is conducting clinical research on this drug for gastrointestinal stromal tumors.
DCC-2618 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being evaluated in clinical trials for safety and efficacy.
DCC-2618 has been studied in one completed Phase 2 clinical trial with the identifier NCT04282980. This trial enrolled 39 participants with advanced gastrointestinal stromal tumors and was conducted in China.
Yes, DCC-2618 is also known as ripretinib. The clinical trial NCT04282980 refers to the drug as DCC-2618 (Ripretinib), confirming that these names refer to the same investigational compound.